Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Accumulated Expenses (2024 - 2025)

Humacyte has reported Accumulated Expenses over the past 2 years, most recently at $185000.0 for Q4 2025.

  • Quarterly results put Accumulated Expenses at $185000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $185000.0 (changed N/A YoY), and the annual figure for FY2025 was $185000.0, changed.
  • Accumulated Expenses for Q4 2025 was $185000.0 at Humacyte, down from $10.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for HUMA hit a ceiling of $11.2 million in Q3 2024 and a floor of $185000.0 in Q4 2025.